Analyst consensus rating
Sarepta Therapeutics Analyst Rating: Hold
Direct answer
Sarepta Therapeutics's consensus rating is Hold.
22 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.64.
Forecast evidence checked October 17, 2026.
Get free Sarepta Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $17.10
- Average price target
- $21.64
- High price target
- $38.00
- Low price target
- $5.00
- Low target gap
- -70.8%
- Target upside
- +26.5%
- High target gap
- +122.2%
- Target range width
- 193%
- Consensus rating
- Hold
- Analysts
- 22
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sarepta Therapeutics?
Sarepta Therapeutics has a verified Hold consensus. The same dataset has an average price target of $21.64.
How far are Sarepta Therapeutics's low and high targets from the recorded price?
The low target implies -70.8%, while the high target implies +122.2%.
How many analysts are included in Sarepta Therapeutics's consensus?
The verified consensus includes 22 analysts.
How is Sarepta Therapeutics's target upside or downside calculated?
The average target of $21.64 is divided by the recorded price of $17.10, then one is subtracted to produce +26.5%. This does not guarantee a future return.
When was Sarepta Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.